OncoMatch/Clinical Trials/NCT05352178
Metastasis-directed Therapy for Oligorecurrent Prostate Cancer
Is NCT05352178 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies multiple treatments including Androgen deprivation therapy and Androgen receptor targeted therapy for prostate cancer.
Treatment: Androgen deprivation therapy · Androgen receptor targeted therapy — The aim is to investigate whether the addition of short-term androgen deprivation therapy (ADT) during 1 month or short-term ADT during 6 months together with an androgen receptor targeted therapy (ARTA) to metastasis-directed therapy (MDT) significantly prolongs poly-metastatic free survival (PMFS) and/or metastatic castration-refractory prostate cancer free survival (mCRPC-FS) in patients with oligorecurrent hormone sensitive prostate cancer.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Prostate Cancer
Tumor Agnostic
Disease stage
Metastatic disease required
Performance status
WHO 0–2
Demographics
Prior therapy
Must have received: radical prostatectomy
radical prostatectomy
Must have received: postoperative radiotherapy
postoperative radiotherapy
Cannot have received: LHRH agonist
PSA rise while on active treatment (LHRH-agonist, LHRH antagonist, anti-androgen, maximal androgen blockade, oestrogen)
Cannot have received: LHRH antagonist
PSA rise while on active treatment (LHRH-agonist, LHRH antagonist, anti-androgen, maximal androgen blockade, oestrogen)
Cannot have received: antiandrogen
PSA rise while on active treatment (LHRH-agonist, LHRH antagonist, anti-androgen, maximal androgen blockade, oestrogen)
Cannot have received: maximal androgen blockade
PSA rise while on active treatment (LHRH-agonist, LHRH antagonist, anti-androgen, maximal androgen blockade, oestrogen)
Cannot have received: oestrogen
PSA rise while on active treatment (LHRH-agonist, LHRH antagonist, anti-androgen, maximal androgen blockade, oestrogen)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05352178 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior LHRH agonist, LHRH antagonist, antiandrogen disqualifies patients from enrollment.
Is this trial open to female patients?
No. This trial enrolls male patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages